AARDEX Group

Important milestone in managing adherence to anti-osteoporosis treatment

AARDEX’s scientific lead Bernard Vrijens is a co-author of the new publication in the Osteoporosis International journal about determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment.

AARDEX’s scientific lead Bernard Vrijens is a co-author of the new publication in the Osteoporosis International journal about determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment.

Great team of experts who met to define a strong consensus under the auspices of the WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing.

Publication title:
Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)

Journal: Osteoporosis International, 30(11), 2155-2165

DOI: 10.1007/s00198-019-05104-5

Access the publication here

Share This Post

You may also like...